# START-MET (NCT05209243)

> START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC

No report yet. It can be ordered.

- Drugs tested: none (the trial tests a strategy, not a drug)
- Indication: castration sensitive oligometastatic prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05209243
- Phase: NA
- Status: RECRUITING
- Sponsor: Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
- Conditions: Prostate Cancer; Stereotactic Body Radiation Therapy
- Interventions: SBRT; STANDARD OF CARE
- Enrollment: 266
- Primary outcome: Radiological progression-free survival (rPFS)

## Indexed commentary on START-MET so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 5 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=start-met-nct05209243